Hodgkin Lymphoma
Introduction
Hodgkin lymphoma (HL) is a type of cancer that originates from B lymphocytes, a crucial component of the immune system. [1] It is one of the more common cancers diagnosed in adolescents and young adults. [1] Historically, studies involving identical twins have indicated a genetic predisposition to the young-adult form of the disease. [2]
Biological Basis
HL is broadly classified into two main forms: classical Hodgkin lymphoma (cHL), which accounts for approximately 95% of cases, and the less common nodular lymphocyte-predominant HL. [1] Classical HL is characterized by the presence of Hodgkin and Reed-Sternberg (HRS) cells, which are malignant B cells, interspersed within a reactive inflammatory microenvironment. cHL is further subdivided into four histological subtypes, including nodular sclerosis HL (NSHL) and mixed cellularity HL (MCHL). [1] The biological basis of HL involves complex genetic and immunological factors. For instance, the inhibition of NF-κB in HRS cells can lead to apoptosis. [3] Key transcription factors such as EBF1 and RUNX3 are also implicated; EBF1 expression is often low in HRS cells, contributing to the loss of a normal B-cell phenotype, while RUNX3 plays a role in B-cell maturation. [3]
Genome-wide association studies (GWAS) have been instrumental in identifying genetic susceptibility loci for HL. Multiple regions within the human leukocyte antigen (HLA) complex on chromosome 6p21.3 have been associated with HL risk, including specific HLA class I and class II alleles like HLA-DPB1*03:01 and variants in HLA-DRB1, HLA-DRA, MICB, HLA-A, and HCG9. [4] Beyond the HLA region, other susceptibility loci have been identified, such as those at 2p16.1 (REL), 8q24.21, 10p14 (GATA3), 6q22.33, 3q28, and 6q23.3. [5] These risk loci often reside in areas of active chromatin and show enrichment for transcription factor binding sites relevant to B-cell development and immune response. [3] The Epstein-Barr virus (EBV) is another significant factor, with studies investigating its role in defining subgroups of HL and its interaction with genetic susceptibility. [6]
Clinical Relevance and Social Importance
The identification of these genetic variants contributes to a deeper understanding of HL etiology, which can inform risk assessment and potentially lead to advancements in diagnosis and targeted therapies. Given its prevalence among adolescents and young adults, HL has considerable social importance, impacting patients during critical developmental stages. Research into the genetic underpinnings of HL, including its subtypes and EBV status, helps to identify key regulators of disease susceptibility, offering avenues for improved clinical management and public health strategies. [3]
Methodological and Statistical Constraints
Current genome-wide association studies (GWAS) for Hodgkin lymphoma (HL) face several methodological and statistical limitations that impact the comprehensiveness and interpretation of findings. A significant challenge arises from insufficient statistical power, particularly for detecting associations involving rare genetic variants or less common HL subtypes, such as Epstein-Barr virus (EBV)-positive classical HL. [1] While some studies report adequate power for common variants with larger effect sizes, smaller risk estimates or rarer alleles may remain undetected. [1] Furthermore, the incomplete genomic coverage inherent in GWAS, compared to newer methods like whole-exome sequencing, means that a complete view of the human genome is not achieved, potentially missing important associations. [7]
The analytical approaches also present constraints, such as the need for multiple-hypothesis correction in meta-analyses, which can raise the threshold for genome-wide significance and thus limit the discovery of new loci. [7]
Ancestry and Phenotypic Specificity
The generalizability of genetic findings for Hodgkin lymphoma is often limited by the demographic characteristics of the study populations. Many large-scale GWAS and meta-analyses predominantly include individuals of European ancestry . Conversely, rs6903608 shows a specific association with EBV-negative cHL and is predominantly linked to the nodular sclerosis histological subtype of HL. [1] Another key variant, rs28383311, located in the region between _HLA-DRB1_ and _HLA-DQA1_, further underscores the importance of this region. _HLA-DRB1_ variations, such as the Val86 residue, are recognized as independent risk loci for nodular sclerosis Hodgkin lymphoma, highlighting the fine-tuned genetic influences on disease subtypes. [3] The expression levels of _HLA-DQA1_ probes are also associated with certain SNPs, suggesting an alternative mechanism underlying observed genetic associations in lymphoid malignancies. [8]
Beyond the HLA region, several other genes and their associated variants are considered in the context of Hodgkin lymphoma susceptibility. For example, the variant rs559464313 in the _DRD4_ gene, which encodes a dopamine receptor, may influence immune cell function and neuroendocrine pathways that can impact cancer development. Similarly, rs377333979 in _RNF141_ (Ring Finger Protein 141) could alter protein ubiquitination, a process crucial for regulating cell cycle, DNA repair, and apoptosis, with implications for uncontrolled cell growth characteristic of lymphoma. Variants like rs547573644 in the _LPAR1_ - _RNY4P18_ intergenic region might affect lysophosphatidic acid signaling, known to be involved in cell proliferation and survival, or modulate the expression of nearby genes through non-coding RNA mechanisms. These loci, identified in broad genome-wide association studies, suggest a complex interplay of genetic factors contributing to HL risk. [3]
Further genetic insights come from variants such as rs75229018 within the _LINC02838_ - _GDI2P1_ intergenic region. _LINC02838_ is a long intergenic non-coding RNA, which can regulate gene expression and cellular processes, while _GDI2P1_ is a pseudogene, potentially influencing the regulation of its functional counterpart. rs576160676 in _GALNTL5_ (UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase-like 5) could impact protein glycosylation, a modification that affects protein function, cell-cell interactions, and immune recognition, all relevant to cancer progression. The variant rs565643303 in _TTL_ (Tubulin Tyrosine Ligase) might alter microtubule dynamics, which are essential for cell division and migration, thus potentially influencing the spread or development of lymphoma. These non-HLA variants highlight the diverse biological pathways that can contribute to Hodgkin lymphoma susceptibility, moving beyond direct immune presentation to include cellular metabolism, signaling, and structural integrity. [1]
Lastly, the _PACERR_ - _PLA2G4A_ intergenic region, with variant rs532391514, may impact lipid metabolism or p53-associated regulatory functions, as _PLA2G4A_ encodes a phospholipase involved in inflammation and _PACERR_ is a p53-associated non-coding RNA. Alterations in these pathways can influence cellular stress responses and inflammatory environments conducive to lymphoma. The variant rs1047391271 in _NFIX_ (Nuclear Factor I X), a transcription factor, could modulate gene expression critical for B-cell development and differentiation. Dysregulation of _NFIX_ activity might impair normal lymphoid development, contributing to the malignant transformation seen in Hodgkin lymphoma. The collective impact of these diverse genetic variants illustrates the multifaceted nature of HL susceptibility, encompassing both immune-specific and general cellular regulatory mechanisms.
Definition and Core Characteristics of Hodgkin Lymphoma
Hodgkin lymphoma (HL) is precisely defined as a malignant condition originating from B lymphocytes, notably recognized as one of the more common cancers affecting adolescents and young adults. [1] This malignancy is broadly categorized into two primary forms: classical Hodgkin lymphoma (cHL) and the less prevalent nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL). [1] Classical HL, which constitutes approximately 95% of all HL cases, is pathologically distinguished by the presence of a small number of characteristic Hodgkin and Reed-Sternberg (HRS) tumor cells. [1] These unique HRS cells are typically scattered within a rich and diverse inflammatory cellular microenvironment. [1] Further molecular insights indicate that mutations in NFKBIA are a recurrent finding in cHL, although they do not serve as a unifying feature for cases not associated with Epstein-Barr virus (EBV); additionally, low expression of EBF1 in HRS cells is believed to contribute to their loss of normal B-cell phenotype. [3]
Classification Systems and Histological Subtypes
The classification of Hodgkin lymphoma follows a structured nosological system, primarily guided by the World Health Organization (WHO) classification of hematopoietic and lymphoid tissues. [9] This system broadly divides HL into classical Hodgkin lymphoma (cHL) and nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL). [1] Classical HL is further subdivided into four distinct histological subtypes: nodular sclerosis HL (NSHL), mixed cellularity HL (MCHL), lymphocyte-depleted HL, and lymphocyte-rich HL. [1] For epidemiological research, the International Lymphoma Epidemiology Consortium (InterLymph) Pathology Working Group has developed a hierarchical classification system, which is based on the WHO classification, to standardize phenotype data and facilitate research into lymphoid neoplasms. [10] Within this framework, cHL cases can also be subgrouped based on a combined assessment of their tumor histology and Epstein-Barr virus (EBV) status, providing a more refined classification for research and potentially clinical stratification. [1]
Genetic Susceptibility and Key Research Terminology
Genetic predisposition plays a significant role in Hodgkin lymphoma susceptibility, with numerous loci identified through genome-wide association studies (GWAS). [4] A prominent area of susceptibility is the HLA class II region, where specific alleles such as HLA-DPB1*03:01 and Val86 HLA-DRB1 have been implicated. [11] The 8.1 ancestral haplotype (A1, B8, DR3) is also recognized for its association with various immunopathological diseases, including HL. [11] Beyond the HLA region, a novel susceptibility locus at 19p13.3, involving the TCF3 gene, has been identified for Hodgkin lymphoma. [12] In the context of GWAS, rigorous quality control measures are essential, including the exclusion of single nucleotide polymorphisms (SNPs) with low call rates or a minor allele frequency (MAF) below 0.01, and the removal of samples exhibiting low call rates, extreme heterozygosity, or gender discordance, to ensure data integrity and reliable identification of genetic variants. [13]
Clinical Phenotypes and Disease Classification
Hodgkin lymphoma (HL) is a malignant condition originating from B lymphocytes, frequently presenting in adolescents and young adults. [1] The disease is broadly categorized into two major forms: classical Hodgkin lymphoma (cHL), which constitutes approximately 95% of cases, and the less prevalent nodular lymphocyte-predominant HL. [1] Classical HL is histologically characterized by the presence of a small number of distinctive Hodgkin and Reed–Sternberg (HRS) tumor cells, which are scattered within a reactive inflammatory cell milieu. [1] This dominant form is further subdivided into four specific histological subtypes: nodular sclerosis HL (NSHL), mixed cellularity HL (MCHL), lymphocyte-depleted HL, and lymphocyte-rich HL, each representing a distinct clinical phenotype with varying presentation patterns. [1]
Diagnostic Evaluation and Subtype Characterization
The definitive diagnosis and precise classification of Hodgkin lymphoma cases are performed through a rigorous pathological review process, which adheres to the World Health Organization (WHO) classification scheme as applied by the InterLymph Pathology Working Group. [13] This comprehensive diagnostic approach involves the central review of phenotypic information, primarily relying on histopathological examination to identify the hallmark HRS cells and accurately determine the specific cHL subtype. [13] Furthermore, the tumor's Epstein–Barr virus (EBV) status serves as an important diagnostic criterion that helps define specific subgroups of cHL, contributing to a more refined characterization of the disease. Molecular analyses, such as the identification of recurrent mutations in NFKBIA, which encodes IkappaB alpha, also offer diagnostic insights, though these mutations are not a consistent feature across all non-EBV-associated cases. [3]
Heterogeneity and Clinical Correlations
Significant heterogeneity in Hodgkin lymphoma presentation is evident through variations in age and sex distribution across its subtypes. For example, nodular sclerosis HL (NSHL) typically presents at a younger mean age of 31.4 years, with a reported range of 15-49 years, whereas mixed cellularity HL (MCHL) often affects older individuals, showing a mean age at diagnosis of 46.9 years and a wider range of 15-86 years. [14] These age-related differences, alongside observed sex variations in patient cohorts (e.g., differing male proportions in NSHL and MCHL series), highlight the diverse clinical patterns of the disease. [14] The diagnostic significance of these phenotypic distinctions, including histological subtype and EBV status, is paramount for accurate differential diagnosis, serves as a crucial prognostic indicator, and can reflect underlying etiological factors such as prior EBV infection. [1]
Genetic Predisposition and Susceptibility Loci
Genetic factors play a significant role in determining an individual's susceptibility to Hodgkin's lymphoma. Studies on identical twins have revealed a concordance for the disease, particularly for the young-adult form, strongly suggesting an inherited genetic component. [2] Genome-wide association studies (GWAS) have identified numerous risk loci, including those on chromosomes 2p16.1 (REL), 8q24.21, and 10p14 (GATA3). [5] The Human Leukocyte Antigen (HLA) region on chromosome 6p21.3 is a particularly significant susceptibility locus, with specific alleles like HLA-A*02 associated with a reduced risk and HLA-A*01 with an increased risk for Epstein-Barr virus (EBV)-positive Hodgkin lymphoma. [5]
Further research has uncovered additional risk loci for classical Hodgkin lymphoma at 6q22.33 (rs9482849) and for nodular sclerosis Hodgkin lymphoma at 3q28 (rs4459895), 6q23.3 (rs6928977), and 10p14 (rs3781093). [3] Other identified loci include 3p24.1 (rs3806624), which localizes 5’ to the EOMES gene and affects p53 binding, and 6q23.3 (rs7745098), mapping intergenic to HBS1L and MYB, genes associated with hematopoiesis. [14] These genetic variations often reside in areas of active chromatin and influence the binding of transcription factors crucial for B-cell development and immune responses, highlighting the complex polygenic nature of Hodgkin's lymphoma susceptibility. [3] Mutations in NFKBIA, encoding IkappaB alpha, have also been recurrently observed in classical Hodgkin lymphoma. [3]
Viral Infections and Immune System Modulation
Infectious agents, particularly the Epstein-Barr virus (EBV), are strongly implicated in the etiology of Hodgkin's lymphoma. Infectious mononucleosis, caused by EBV, has a specific association with EBV-positive Hodgkin lymphoma, especially in young adults, indicating that prior infection is a key etiological factor. [6] The presence of EBV in Hodgkin and Reed-Sternberg (HRS) cells is a defining characteristic in a subset of cases, influencing disease incidence and progression. [15]
The virus actively modulates the immune system and cellular processes, contributing to lymphomagenesis. For instance, EBV-driven lymphoblastoid cell lines require the downregulation of RUNX1 by RUNX3, illustrating the intricate mechanisms through which viral infection influences the malignant transformation of B-cells. [3] The spectrum of EBV-associated diseases further underscores its multifaceted role in various lymphoproliferative disorders, including Hodgkin's lymphoma. [16]
Environmental and Lifestyle Factors
Beyond genetic predispositions and viral infections, a range of environmental and lifestyle factors contribute to the risk of Hodgkin's lymphoma. Exposure to certain environmental elements, such as ultraviolet radiation, has been investigated for its potential role in disease development. [8] Lifestyle choices, including smoking and alcohol consumption, may modify the risk of both EBV-positive and EBV-negative Hodgkin lymphoma, suggesting potential interactions with other etiological factors. [17]
Socioeconomic factors and aspects of the childhood social environment have also been linked to an altered risk of Hodgkin lymphoma. [18] Additionally, obesity has been identified as a lifestyle factor associated with an increased risk of developing the condition. [19] These diverse environmental and lifestyle influences highlight the multifactorial nature of Hodgkin's lymphoma development.
Gene-Environment Interactions and Cellular Development
The pathogenesis of Hodgkin's lymphoma often involves complex interactions between an individual's genetic makeup and environmental exposures. A prime example is the interplay between specific HLA alleles and EBV infection, where certain HLA types modulate the risk of developing EBV-positive Hodgkin lymphoma. [5] This demonstrates how genetic predisposition can interact with viral triggers to influence disease susceptibility.
Genetic risk loci frequently localize to areas of active chromatin and affect the binding of transcription factors critical for B-cell development and immune function. [3] This suggests that epigenetic mechanisms, which involve modifications to DNA and histones that regulate gene expression without altering the underlying DNA sequence, play a role in disease development. Early life influences, including aspects of the childhood social environment, can also interact with genetic susceptibilities, collectively shaping the overall risk profile. [18] The dysregulation of B-cell maturation, involving key genes like EBF1 and RUNX3, represents a critical developmental mechanism in Hodgkin's lymphoma, contributing to the characteristic loss of normal B-cell phenotype in malignant cells. [3]
Biological Background of Hodgkin Lymphoma
Hodgkin lymphoma (HL) is a malignant condition originating from B lymphocytes, primarily affecting adolescents and young adults. It is broadly categorized into two main forms: classical Hodgkin lymphoma (cHL), which constitutes approximately 95% of cases, and the less common nodular lymphocyte-predominant HL. Classical HL is histologically characterized by a small number of distinctive Hodgkin and Reed–Sternberg (HRS) tumor cells dispersed within a predominant inflammatory cell infiltrate, and is further subdivided into nodular sclerosis HL (NSHL), mixed cellularity HL (MCHL), lymphocyte-depleted HL, and lymphocyte-rich HL. [1] Genetic susceptibility plays a role in the development of HL, as evidenced by observed concordance in identical twins. [2]
Cellular Origins and Pathological Hallmarks
Classical Hodgkin lymphoma is defined by the presence of Hodgkin and Reed–Sternberg (HRS) cells, which are typically malignant B-lymphocytes that have undergone an aberrant transformation and lost many characteristic B-cell features. These HRS cells are scattered within a reactive microenvironment composed of various inflammatory cells, including lymphocytes, plasma cells, eosinophils, and histiocytes. [1] This unique microenvironment is not merely a bystander but an actively shaped and essential component of the tumor, contributing to its survival and growth. [20] The loss of normal B-cell phenotype in HRS cells is a critical aspect of HL pathology, often associated with altered gene expression patterns, such as the low expression of EBF1. [3]
Genetic Predisposition and Immune System Regulation
Genome-wide association studies (GWAS) have identified several genetic loci that influence susceptibility to Hodgkin lymphoma, including specific subtypes like nodular sclerosis Hodgkin lymphoma (NSHL) and mixed cellularity Hodgkin lymphoma (MCHL). [1] A significant portion of these susceptibility loci are found within the human leukocyte antigen (HLA) region on chromosome 6p21.3. [14] Variants such as HLA-DPB1*03:01 and specific amino acid variations like Val86 in HLA-DRB1 are associated with NSHL, while other variants like rs1633096, rs13196329, and Val86 in HLA-DRB1 are linked to MCHL. [3] The HLA-B gene, encoding a class I heavy chain protein, is crucial for presenting intracellular antigens to CD8+ cytotoxic T lymphocytes, and its alleles, such as HLA-B*08:01, show strong associations, highlighting the central role of immune recognition in HL pathogenesis. [4] Beyond the HLA region, other susceptibility loci have been identified, including rs9482849 at 6q22.33 for all cHL, and rs4459895 at 3q28, rs6928977 at 6q23.3, and rs3781093 at 10p14 specifically for NSHL. [3] Additional risk loci include 2p16.1 (REL), 8q24.21, and 10p14 (GATA3). [5] These genetic variations often localize to active chromatin regions and are enriched for transcription factor binding sites involved in B-cell development and immune responses, suggesting their regulatory roles in disease susceptibility. [3]
Molecular Dysregulation in B-cell Development
The pathogenesis of Hodgkin lymphoma involves significant molecular dysregulation, particularly affecting pathways crucial for B-cell development and function. Transcription factors such as EBF1, E2A, and PAX5 are essential regulators of B-cell maturation, and their altered expression, like the low EBF1 levels observed in HRS cells, contributes to the loss of a normal B-cell phenotype. [3] The NF-κB signaling pathway is also critically involved; its inhibition in HRS cells can induce caspase-independent apoptosis, and recurrent mutations in NFKBIA, which encodes the IκBα protein, are a common finding in cHL. [3] Other key transcription factors include RUNX3, which plays important roles in B-cell maturation and the regulation of RUNX1 during Epstein-Barr virus (EBV)-driven lymphoblastoid cell line (LCL) development. [3] Furthermore, the NF-κB subunit c-Rel is known to regulate the expression of the Bach2 tumor suppressor, a repressor involved in antibody class switching, underscoring the complex interplay of these molecules in lymphoma development. [21]
Role of Epstein-Barr Virus and Tumor Microenvironment
Epstein-Barr virus (EBV) is implicated in the etiology of a subset of Hodgkin lymphoma cases, and the EBV status of tumors is used to define distinct subgroups of cHL. [1] This virus is known for its ability to transform B-cells and is associated with a spectrum of diseases, including various lymphomas. [16] The interaction between EBV and cellular transcription factors, such as RUNX3, can influence cellular processes like the downregulation of RUNX1, which is essential for EBV-driven LCLs. [3] The tumor microenvironment, rich in inflammatory cells, is not merely a passive bystander but actively supports the HRS cells, contributing to immune evasion and tumor progression. [20] This complex cellular milieu, orchestrated by various chemokines and cytokines, facilitates the survival and proliferation of malignant cells, further highlighting the systemic consequences of the disease beyond the primary tumor site.
Oncogenic Signaling and Transcriptional Reprogramming
Hodgkin's lymphoma (HL) pathogenesis is heavily influenced by dysregulated signaling pathways and altered transcriptional programs that promote the survival and proliferation of Hodgkin Reed-Sternberg (HRS) cells. A central mechanism involves the constitutive activation of the nuclear factor-kappaB (NF-κB)-RelA pathway, which is essential for the proliferation and survival of Hodgkin’s disease tumor cells. [3] This activation can be further influenced by factors such as AZI2, which contributes to NF-κB activation. [22] Beyond NF-κB, a complex network of transcription factors, including E2A, EBF1, and Foxo1, normally orchestrates B cell fate; however, in HRS cells, low expression of EBF1 is observed, contributing to the characteristic loss of normal B-cell phenotype. [3] Furthermore, the NF-κB subunit c-Rel plays a role in regulating the Bach2 tumor suppressor, which is involved in the transcriptional program of antibody class switching, highlighting intricate regulatory loops . The BCL2 gene family, known for its role in apoptosis, also exhibits dysregulation in B-cell malignancies, impacting cell survival . Moreover, mechanisms of immune suppression, such as the inhibition of T cell function by PD-1 through the upregulation of BATF, demonstrate how HRS cells can subvert host immunity . Genome-wide association studies (GWAS) have identified numerous germline genetic susceptibility loci for classical HL (cHL) and its subtypes, revealing distinct genetic profiles compared to other lymphoid malignancies. [23] For instance, a locus at 6q22.33 (rs9482849) is associated with overall cHL risk, while nodular sclerosis HL (NSHL) is linked to variants at 3q28 (rs4459895), 6q23.3 (rs6928977), 10p14 (rs3781093), (rs112998813), and (rs34972832). [3] Additionally, variations at 3p24.1 and 6q23.3 have been shown to influence HL risk. [14]
These genetic insights are crucial for refining risk stratification models and potentially identifying individuals at higher risk for developing HL. Specific independent loci within the human leukocyte antigen (HLA) region, such as rs9269081, HLA-DPB1*03:01, and Val86 in HLA-DRB1, are associated with NSHL, while mixed cellularity HL (MCHL) shows associations with rs1633096, rs13196329, and Val86 in HLA-DRB1. [3] Another susceptibility locus, 19p13.3 TCF3, has also been identified through meta-analysis. [12] The localization of these risk loci to active chromatin regions and their over-representation in transcription factor binding sites relevant to B-cell development and immune response underscore their functional significance and potential for future targeted prevention strategies or early detection in high-risk populations. [3]
Etiological Associations and Disease Phenotypes
The clinical presentation and progression of Hodgkin's lymphoma are significantly influenced by associated etiological factors, particularly infectious agents. Epstein-Barr virus (EBV) status is a critical factor in classifying classical HL (cHL) subgroups, with specific genetic associations varying between EBV-positive and EBV-negative tumors. [1] Prior infection by EBV and other agents are known risk factors for Hodgkin's disease, highlighting the role of infectious etiology in lymphoma development. [6] Furthermore, HIV infection is associated with an increased risk of various cancers, including lymphomas, and differences in virological and immunological risk factors between Hodgkin and non-Hodgkin lymphomas have been observed in HIV-infected individuals. [24]
Understanding these associations is vital for patient care, informing risk assessment, especially in immunocompromised individuals. At a molecular level, mutations in NFKBIA, which encodes IkappaB alpha, are frequently found in cHL, though they do not uniformly characterize non-EBV-associated cases. [3] The low expression of EBF1 in Hodgkin and Reed-Sternberg (HRS) cells is also thought to contribute to the loss of normal B-cell phenotype, which is a hallmark of the disease. [3] These molecular insights, alongside infectious associations, contribute to a comprehensive understanding of disease pathogenesis and may guide future therapeutic strategies.
Diagnostic Precision and Prognostic Implications
Accurate diagnostic classification is fundamental for guiding treatment and predicting outcomes in Hodgkin's lymphoma, which is broadly categorized into classical HL (cHL) and nodular lymphocyte-predominant HL, with cHL further subdivided into distinct histological subtypes such as nodular sclerosis HL (NSHL) and mixed cellularity HL (MCHL). [1] The identification of specific genetic loci associated with these subtypes, particularly within the HLA region, offers potential avenues for enhanced diagnostic precision and risk assessment. [3] For example, specific HLA alleles and single nucleotide polymorphisms (SNPs) have been linked to either NSHL or MCHL, suggesting that genetic profiling could refine subtyping.
Beyond diagnosis, the understanding of these genetic and etiological factors holds prognostic value, influencing predictions of disease progression and treatment response. The functional implications of identified risk loci, particularly their involvement in B-cell development and immune responses, suggest that these genetic markers could serve as indicators for long-term outcomes. [3] Integrating germline genetic profiles with clinical and pathological features, including EBV status, can contribute to personalized medicine approaches, allowing for more tailored monitoring strategies and treatment selection based on an individual's specific risk profile and disease characteristics.
Key Variants
| RS ID | Gene | Related Traits |
|---|---|---|
| rs6903608 rs2395185 |
HLA-DRB9 | hodgkins lymphoma nodular sclerosis Hodgkin lymphoma |
| rs559464313 | DRD4 | hodgkins lymphoma |
| rs28383311 | HLA-DRB1 - HLA-DQA1 | hodgkins lymphoma |
| rs377333979 | RNF141 | hodgkins lymphoma |
| rs547573644 | LPAR1 - RNY4P18 | hodgkins lymphoma |
| rs75229018 | LINC02838 - GDI2P1 | hodgkins lymphoma |
| rs576160676 | GALNTL5 | hodgkins lymphoma |
| rs565643303 | TTL | hodgkins lymphoma |
| rs532391514 | PACERR - PLA2G4A | hodgkins lymphoma |
| rs1047391271 | NFIX | hodgkins lymphoma |
Frequently Asked Questions About Hodgkins Lymphoma
These questions address the most important and specific aspects of hodgkins lymphoma based on current genetic research.
1. My identical twin had Hodgkin lymphoma; am I at risk?
Yes, studies in identical twins show a higher chance of both twins developing Hodgkin lymphoma, suggesting a strong genetic predisposition. Specific genetic variations, especially in your immune system's HLA complex, can influence this shared risk. While genetics play a significant role, it's not a guarantee, and other factors are involved.
2. Why do some people get Hodgkin lymphoma and others don't?
It's complex, but your genetics play a big role in why some people are more susceptible. Many specific regions in your DNA, especially those involved in immune function like the HLA complex, have been linked to an increased risk. These genetic differences can make your body's B cells more vulnerable to becoming cancerous.
3. Does getting sick often mean I'm more at risk?
Not necessarily just getting sick, but your immune system's genetic makeup is very important. Specific genetic variations in your HLA complex, which helps your immune system recognize invaders, are strongly linked to Hodgkin lymphoma risk. Also, certain viruses like Epstein-Barr virus (EBV) can interact with your genetic susceptibility to increase risk.
4. Does my ethnic background change my Hodgkin lymphoma risk?
Yes, your ethnic background can influence your risk. Most genetic studies have focused on people of European ancestry, meaning we might not fully understand specific risk factors or protective genes in other populations. Different ancestral groups may have unique genetic variations that affect their susceptibility.
5. Can I reduce my risk with a healthy lifestyle?
While a healthy lifestyle is always beneficial, Hodgkin lymphoma has a strong genetic component, with many identified genetic susceptibility loci. These genes influence your immune system and B-cell development, making some people inherently more prone to the disease. However, understanding your genetic risk can inform personalized prevention strategies and early detection.
6. Why is Hodgkin lymphoma common in young adults?
Hodgkin lymphoma is indeed more common in adolescents and young adults, and genetic predisposition plays a significant role in this young-adult form of the disease. While the exact reasons for this age specificity are still being researched, it's thought to involve specific genetic factors that influence B-cell development and immune responses during these critical developmental stages.
7. Is a genetic test useful to know my personal risk?
Yes, genetic testing can be useful in understanding your personal risk. Researchers have identified several specific genetic variations, particularly within the HLA complex and other genes like REL and GATA3, that increase susceptibility to Hodgkin lymphoma. Knowing about these variants can help inform risk assessment and may guide future personalized medical approaches.
8. My sibling got it, but I didn't; why the difference?
Even with shared family genetics, individual risk can vary. While genetic factors like specific HLA alleles predispose you, Hodgkin lymphoma development is complex. It involves a combination of many genetic variations and potentially environmental factors like exposure to viruses such as EBV, making each sibling's outcome unique.
9. Does my body's immune response play a role in my risk?
Absolutely. Hodgkin lymphoma starts in B lymphocytes, a key part of your immune system. Genetic variations in regions like the HLA complex significantly influence how your immune system responds to threats and develops B cells. These genetic predispositions can make your B cells more vulnerable to becoming cancerous.
10. Can a common virus increase my risk for Hodgkin lymphoma?
Yes, a common virus like Epstein-Barr virus (EBV) is a significant factor. Studies show EBV interacts with your genetic susceptibility, especially for certain subtypes of classical Hodgkin lymphoma. If you have specific genetic predispositions, exposure to EBV can further increase your risk.
This FAQ was automatically generated based on current genetic research and may be updated as new information becomes available.
Disclaimer: This information is for educational purposes only and should not be used as a substitute for professional medical advice. Always consult with a healthcare provider for personalized medical guidance.
References
[1] Urayama KY et al. "Genome-wide association study of classical Hodgkin lymphoma and Epstein-Barr virus status-defined subgroups." J Natl Cancer Inst, 2012.
[2] Mack, T. M., et al. "Concordance for Hodgkin's disease in identical twins suggesting genetic susceptibility to the young-adult form of the disease." N. Engl. J. Med., vol. 332, no. 7, 1995, pp. 413–419.
[3] Sud A et al. "Genome-wide association study of classical Hodgkin lymphoma identifies key regulators of disease susceptibility." Nat Commun, 2017.
[4] Cerhan, J. R., et al. "Localization of predisposition to Hodgkin disease in the HLA class II region." Am J Hum Genet, vol. 54, no. 3, 1994, pp. 497-505.
[5] Enciso-Mora, V., et al. "A genome-wide association study of Hodgkin's lymphoma identifies new susceptibility loci at 2p16.1 (REL), 8q24.21 and 10p14 (GATA3)." Nat Genet, vol. 42, no. 12, 2010, pp. 1126-1130.
[6] Alexander, F. E., et al. "An epidemiologic study of index and family infectious mononucleosis and adult Hodgkin’s disease (HD): evidence for a specific association with EBV+ve HD in young adults." Int J Cancer, vol. 107, 2003, pp. 298–302.
[7] Din, L., et al. "Genetic overlap between autoimmune diseases and non-Hodgkin lymphoma subtypes." Genetic Epidemiology, vol. 43, no. 7, 2019, pp. 838-849, PMID: 31407831.
[8] Smedby KE et al. "GWAS of follicular lymphoma reveals allelic heterogeneity at 6p21.32 and suggests shared genetic susceptibility with diffuse large B-cell lymphoma." PLoS Genet, 2011.
[9] Swerdlow, Steven H., et al. World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues. IARC Press, 2008.
[10] Morton, Lindsay M., et al. "Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph)." Blood, vol. 110, 2007, pp. 695–708.
[11] Price, P., et al. "The genetic basis for the association of the 8.1 ancestral haplotype (A1, B8, DR3) with multiple immunopathological diseases." Immunological Reviews, vol. 167, 1999, pp. 257-274.
[12] Cozen, W., et al. "A meta-analysis of Hodgkin lymphoma reveals 19p13.3 TCF3 as a novel susceptibility locus." Nat Commun, vol. 5, 2014, p. 3856.
[13] Skibola, Christine F., et al. "Genome-wide association study identifies five susceptibility loci for follicular lymphoma outside the HLA region." Am J Hum Genet, vol. 95, 2014, pp. 462–471.
[14] Frampton, M., et al. "Variation at 3p24.1 and 6q23.3 influences the risk of Hodgkin's lymphoma." Nat Commun, vol. 4, 2013, p. 2714.
[15] Jarrett, R. F., et al. "The Scotland and Newcastle epidemiological study of Hodgkin’s disease: impact of histopathological review and EBV status on incidence estimates." J Clin Pathol, vol. 56, 2003, pp. 811–816.
[16] Kutok, J. L., and F. Wang. "Spectrum of Epstein-Barr virus-associated diseases." Annu Rev Pathol., vol. 1, 2006, pp. 375–404.
[17] Willett, E. V., et al. "Does smoking or alcohol modify the risk of Epstein-Barr virus-positive or -negative Hodgkin lymphoma?" Epidemiology, vol. 18, 2007, pp. 130–136.
[18] Hjalgrim, H., et al. "Infectious mononucleosis, childhood social environment, and risk of Hodgkin lymphoma." Cancer Res, vol. 67, 2007, pp. 2382–2388.
[19] Willett, E. V., and E. Roman. "Obesity and the risk of Hodgkin lymphoma (United Kingdom)." Cancer Causes Control, vol. 17, 2006, pp. 1103–1106.
[20] Liu, Y., et al. "The microenvironment in classical Hodgkin lymphoma: An actively shaped and essential tumor component." Semin Cancer Biol., vol. 21, no. 5, 2011, pp. 373–384.
[21] Muto, A., et al. "The transcriptional programme of antibody class switching involves the repressor Bach2." Nature, vol. 429, no. 6991, 2004, pp. 566–571.
[22] Law, P. J., et al. "Genome-wide association analysis of chronic lymphocytic leukaemia, Hodgkin lymphoma and multiple myeloma identifies pleiotropic risk loci." Sci Rep, vol. 7, 2017, p. 40161.
[23] Berndt, S. I., et al. "Distinct germline genetic susceptibility profiles identified for common non-Hodgkin lymphoma subtypes." Leukemia, 2022.
[24] Thorball, C. W., et al. "Genetic variation near CXCL12 is associated with susceptibility to HIV-related non-Hodgkin lymphoma." Haematologica, vol. 105, no. 12, 2020, pp. 2801-2808.